SHANGHAI, China – While the presidents from the U.S. and China have met in a summit to address human rights and cyber-attack issues, it's become clear that U.S. biopharmaceutical firms have not been immune to targeted hacking out of China. These efforts may have yielded valuable data from clinical trials or drug registration applications.
TAIPEI, Taiwan – It's been a long wait, but Taiwan's drug development industry might just be coming of age. While the island nation is still awaiting its first home-grown innovator drug, a number of companies are almost there.
• Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it obtained an exclusive license from the National Institutes of Health (NIH) to rights on a patent granted in the U.S. for the use of idebenone for the treatment of primary aggressive multiple sclerosis.
LONDON – Autifony Therapeutics Ltd. has started Phase I development of AUT00063, its treatment for age-related hearing loss and tinnitus, and raised a further £5.5 million (US$8.5 million) to take that lead program through to clinical proof of concept.
LONDON – The identification of the exact molecule on the insides of blood vessels to which malaria parasites stick will allow an immediate start on work to develop vaccines and new therapies for severe forms of malaria, the scientists who made the discovery predicted.
DUBLIN, Ireland – Royalty Pharma's bitter and protracted takeover battle for Elan Corp. plc will, one way or another, reach a climax next Monday when Elan shareholders vote on the company's recent M&A deals.
LONDON – Bergenbio AS has raised $6 million in a Series B round supported by all the existing investors, providing funding for a number of Phase I trials of its lead product BGB 324, a first-in-class AXL receptor tyrosine kinase inhibitor.
LONDON – A new study has given hope that it may one day be possible to develop a specific treatment for neuroblastoma, which is a rare type of childhood cancer.
GHENT, Belgium – Patrik De Haes, CEO of Thrombogenics NV, rang the opening bell – albeit remotely – on the NYSE Euronext Brussels exchange to kick off proceedings at the 2013 Knowledge For Growth meeting at the International Convention Center in Ghent, Belgium, last Thursday.
RSS